Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 4;13:921223. doi: 10.3389/fimmu.2022.921223

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Qi, Zhang, Ren, Xu, Yang, Chen, Tu and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The potential role of regulator score in CNV and chemotherapeutic value. (A) The frequency of arm-level amplification and deletion between low and high regulator score groups. (B) The progression-free survival (PFS) curve comparing survival of high and low regulator score groups in a cohort of melanoma patients treated with the combination of anti-PD-1 and anti-CTLA-4. (C) The proportion of clinical response to anti-PD-1 with anti-CTLA-4 immunotherapy in high and low regulator score groups in the melanoma cohort. (D–F) The box plot of the estimated IC50 of MK-2206 (D), erlotinib (E), and Nutlin-3a (F) between low and high regulator score groups. (G–I) The box plot of the predicted drug sensitivity scores of MK-2206 (G), erlotinib (H), and Nutlin-3a (I) between low and high regulator score groups. A lower drug sensitivity score indicated that this group could be more sensitive to the drug therapy. *, p < 0.05.